Condition: Extensive-stage Small-cell Lung Cancer · Sponsor: Pharmacosmos A/S
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
This description comes directly from the study's public registry record.
Pharmacosmos Clinical and non-clinical Department · +45 5948 5959 · info@pharmacosmos.com
Always discuss trial participation with your own doctor first.
| Hospital | Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05874401